PMVP

0.877832.99%
AJ

Arnold J. Levine

Co-Founder, Independent Director & Member of Scientific Advisory Board

Dr. Arnold J. Levine, Ph.D., also known as Arnie, is Member of Scientific Advisory Board of AtlasXomics Inc. He serves as a Member of External Advisory Board of WCG Clinical Inc. Dr. Levine is Member of External Advisory Board at WIRB-Copernicus Group, Inc. and served as its Member of Oncology and Gene Therapy Advisory Board until 2023. He served as Member of Board Advisor at InterVenn Biosciences Inc. He is a Member of Scientific Advisory Board at InnoCare Pharma, Ltd. He served as an Independent Director of MeiraGTx Holdings plc (formerly known as MeiraGTx Limited) since February 2016 until April 21, 2023. He served as Director at Imclone Systems Incorporated from 2000 to 2003. He serves as Director at U.S. National Academy of Sciences, the U.S. National Academy of Medicine and the American Philosophical Society. Dr. Levine served as Member of Scientific Advisory Board at Adaptive Biotechnologies Corporation since May 30, 2019. Dr. Levine serves as Member of Scientific Advisory Board at ROME Therapeutics, Inc. Dr. Levine served as the President and Chief Executive Officer at Rockefeller University from November 1998 to February 2002. Dr. Levine co-founded PMV Pharmaceuticals, Inc. in 2013. He served as the Senior Advisor at Arsenal Capital Partners and focused on BioPharma and Life Sciences. Dr. Levine was employed by Genomica Corp. and Baxter International Inc. He serves as a Co-Chairman of the Board at RDAB Board at BG Medicine, Inc. He serves as a Member of the International Advisory Council at Chugai Pharmaceutical Co. Ltd. He serves as an Director of PMV Pharmaceuticals, Inc. since June 2013. He had been a Member of Scientific Advisory Board at Thermo Fisher Scientific, Inc. since September 2014. He has been an Oncology Advisory Board Member at WIRB - Copernicus Group. He serves as a Member of Scientific Advisory Board at MeiraGTx Holdings plc (formerly known as MeiraGTx Limited). He serves as a Member of Scientific Advisory Board at PMV Pharmaceuticals, Inc. He served as Member of Scientific Advisory Board at Hatteras Venture Advisors VI, LLC (formerly known as Hatteras Venture Partners). He serves as a Member of Scientific Advisory Board of IsoPlexis Corp. He serves as Member of Scientific Advisory Board at Kadmon Holdings, Inc. He served as Member of Scientific Advisory Board at Constellation Pharmaceuticals, Inc. He served as Director of Applied Biosystems, Inc. since 1999, GeneCentric Diagnostics, Inc. (alternate name GeneCentric Therapeutics, Inc.) since September 2012, Applera Corp. since 1999, Infinity Pharmaceuticals, Inc. from September 2006 to May 15, 2012, Celera Corporation since 1999, Selventa, Inc. since November 2, 2010 and Innoviva, Inc. from June 2003 to May 22, 2014. He served as a Member of Scientific Advisory Board of Infinity Pharmaceuticals, Inc. He served as a Director of Adaptive Biotechnologies Corporation until March 2019. He served as Member of Scientific Advisory Board at ExSAR Corporation. Rosetta Genomics, Ltd. Functional Genetics, Inc. and Aureon Biosciences, Inc. He served as a Director of Life Technologies Corporation from November 21, 2008 to April 24, 2013. He served as Director of ExSAR Corporation. He served as Director of Baxter International Inc. since 1994 to 2002. He served as Member of Business Advisory Board at Bay City Capital LLC. Dr. Levine was Editor-in-Chief of the Journal of Virology from 1984 to 1994. He is a widely acclaimed leader in cancer research. In 1979, Dr. Levine and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development. He established the Simons Center for Systems Biology at the Institute for Advanced Study, which concentrates on research at the interface of molecular biology and the physical sciences: on genetics and genomics, polymorphisms and molecular aspects of evolution, signal transduction pathways and networks, stress responses and pharmacogenomics in cancer biology. Dr. Levine helped shape U.S. science priorities as Chairman of an influential 1996 review panel on federal AIDS research funding. He also Chaired the National Cancer Advisory Board, which advises the National Academy of Sciences and its Institute of Medicine on cancer policy. He was elected to the National Academy of Sciences in 1991 and to its Institute of Medicine in 1995. In April 2001, Dr. Levine received the first Albany Medical Center Prize in Medicine and Biomedical Research, the largest annual prize in science or medicine offered in the United States. In 1968 Dr. Levine joined Princeton University as an Assistant Professor, becoming a Professor of biochemistry in 1976, where he was named the Harry C. Wiess Professor in Life Sciences and was the Chairman of the department. In 1979, he moved to the SUNY Stony Brook School of Medicine to Chair the Department of Microbiology. He returned to Princeton in 1984. From 1984 to 1996, he presided over a major expansion of Princeton?s life sciences programs as Chairman of the Department of Molecular Biology. Since 2011, He is a Professor Emeritus at The Simons Center for Systems Biology at the Institute for Advanced Study in Princeton and a joint Professor in the Pediatrics and Biochemistry Departments at the Cancer Institute of New Jersey. He was awarded the 1998 Louisa Gross Horwitz Prize for Biology for Biochemistry and was the first recipient of the Albany Medical Center Prize in Medicine and Biomedical Research in 2001 for his discovery of the tumor suppressor protein p53. He trained as a Postdoctoral Fellow at California Institute of Technology in the laboratory of Robert Sinsheimer. Dr. Levine holds a Ph.D. in Microbiology from Perelman School of Medicine of the University of Pennsylvania and a B.A. In biology from Harpur College, State University of New York. He served as Member Scientific Advisory Board at Dual Therapeutics, LLC. and Cypher Genomics inc.

Positions